Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

This was the stock's second consecutive day of losses.

The stock's fall snapped a two-day winning streak.

HC Wainwright reiterated their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Oppenheimer analyst Jeff Jones reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...

William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened ...

Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based company ...

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval ...

Altria (NYSE: MO), the largest tobacco company in America, is a divisive stock. The bulls love its stable earnings growth and rising dividends, but the bears claim it will eventually run out of ...